Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Medical Therapy Followed by BPA in CTEPH
NCT05140525Phase 3Terminated
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of macitentan and riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms). Primary endpoint: Change in end-systolic elastance divided by arterial elastance at 12 months. Started Jan 2025; status: terminated.
02
Drugs
macitentanriociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT05140525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140525.